# Recent Meta-Analysis Shows CBD’s Potential in MS Treatment > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cbd-treatment-multiple-sclerosis-meta-analysis/ > **Published:** 2022-08-11T19:22:29-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:16:30-04:00 > **Clinical Summary:** Explore how CBD treatment multiple sclerosis shows promise in reducing symptoms and disease progression according to recent meta-analysis findings. --- A recent study looks at the potential benefits of Cannabidiol for the treatment of [multiple sclerosis](https://cedclinic.com/respiratory-function-exercise-therapy-ms/) (MS). The study looks at the immunomodulatory potential for such treatments. A salient takeaway from the meta-analysis is that CBD treatments were consistently effective for reducing the severity of experimental autoimmune encephalomyelitis (EAE). More specifically, CBD treatment was found to contribute to a delayed onset of symptoms, attenuation of clinical signs, and reduced [disease progression](https://cedclinic.com/multiple-sclerosis-biomarkers-p21-protein-variations/). Moreover, a number of studies that were evaluated in the meta-analysis demonstrated that CBD treatment led to improved CNS histology, reduced neuroinflammation, microglia activation, peripheral monocyte and lymphocyte infiltration, and decreased demyelination. Technical jargon aside, this is good news for those suffering from MS and its debilitating symptoms. In total, the meta-analysis assessed 1,808 reports and 29 studies — 26 of which were included in the final review. One such study that was considered found that CBD was comparable to a drug (glatiramer) commonly used to treat MS, insofar as the two treatments demonstrated similar efficacy in reducing EAE. CBD was consistently shown to reduce inflammation in patients. A particular point of interest for future studies is to investigate the issue of target receptors that may be correlated with the effects of CBD. [Read the full study here](https://bit.ly/3AdfCbR) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [A sesquiterpene-rich essential oil from Cannabis sativa L. attenuates symptoms and neuroinflammation in experimental autoimmune encephalomyelitis model through a CB2-mediated signalling.](https://cedclinic.com/cannabis-essential-oil-neuroinflammation-multiple-sclerosis-study/) Explore how cannabis essential oils reduce neuroinflammation and symptoms in MS models via [CB2 receptor](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) pathways. [Learn More](https://cedclinic.com/cannabis-essential-oil-neuroinflammation-multiple-sclerosis-study/) [(—)-ß-Caryophyllene, a Terpine Found in Cannabis, Demonstrates Therapeutic Potential in a Mouse Model of MS](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) Discover the therapeutic effects of ß-Caryophyllene in MS models, highlighting cannabis-derived compounds’ potential. [Read Article](https://cedclinic.com/s-caryophyllene-a-terpine-found-in-cannabis-demonstrates-therapeutic-potential-in-a-mouse-model-of-ms/) [Long-Term Cannabis Therapy May Change MS Spasticity Outcomes](https://cedclinic.com/cannabis-for-ms-spasticity-meta-analysis-2026/) Review meta-analysis findings on how long-term [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) impacts spasticity symptoms in MS patients. [Explore Findings](https://cedclinic.com/cannabis-for-ms-spasticity-meta-analysis-2026/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Recent%20Meta-Analysis%20Shows%20CBD%E2%80%99s%20Potential%20in%20MS%20Treatment&url=https%3A%2F%2Fcedclinic.com%2Fcbd-treatment-multiple-sclerosis-meta-analysis%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcbd-treatment-multiple-sclerosis-meta-analysis%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Recent%20Meta-Analysis%20Shows%20CBD%E2%80%99s%20Potential%20in%20MS%20Treatment%20https%3A%2F%2Fcedclinic.com%2Fcbd-treatment-multiple-sclerosis-meta-analysis%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).